Compare PMI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PMI | MDXH |
|---|---|---|
| Founded | 1981 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.7M | 167.8M |
| IPO Year | 2025 | 2021 |
| Metric | PMI | MDXH |
|---|---|---|
| Price | $2.46 | $3.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | ★ 2.5M | 182.7K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,767,000.00 | ★ $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.81 | ★ 21.68 |
| 52 Week Low | $1.90 | $1.35 |
| 52 Week High | $13.68 | $5.33 |
| Indicator | PMI | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 34.01 |
| Support Level | N/A | $3.31 |
| Resistance Level | N/A | $3.74 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 7.27 |
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.